China SXT Pharmaceuticals (SXTC) Other Accumulated Expenses (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Other Accumulated Expenses for 9 consecutive years, with $877421.0 the latest figure, recorded in Q1 2026.

• Quarterly Other Accumulated Expenses rose 30.11% year-over-year to $877421.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $877421.0 (up 30.11% YoY) and the FY2026 annual result came in at $877421.0, up 30.11% from the prior year.
• Other Accumulated Expenses slipped to $877421.0 in Q1 2026 per SXTC's latest filing, from $920853.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for SXTC reached as high as $6.2 million in Q3 2024 and fell as low as $361543.0 in Q1 2024.
• A 5-year average of $1.4 million and a median of $920853.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses soared 538.65% — and 2025, when it slumped 85.18%.
• Year by year, Other Accumulated Expenses stood at $1.0 million in 2022, then fell by 5.56% to $972738.0 in 2023, then surged by 538.65% to $6.2 million in 2024, then sank by 85.18% to $920853.0 in 2025, then slipped by 4.72% to $877421.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $877421.0, $920853.0, and $674391.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.